IL6 and rheumatoid arthritis: Given that several chronic diseases such as rheumatoid arthritis are characterized by massive presence of autoantibodies, one could hypothesize that the synthetic peptides, potentially deriving from enzymatic cleavage of autoantibodies, via induction of IL-6, could help to trigger or maintain activation of Th17, which is considered a key cell population mediating many chronic inflammatory diseases [40].